|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||3.76 / 9.86|
We exited one position and added to another as volatility returned to the stock market last week.
It was a mixed week for the portfolio as we trimmed one position and added to the Bullpen.
Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the March 16th expiration.
Last week, we closed a position for a large gain and used some of the proceeds to start a small stake in a fracking and desalination name.
Dr. David B. Weiner, Inovio co-founder, and Dr. Jian Yan, Lead Antigen Designer, recognized for their innovative medical and scientific research which led to more than 20 granted U.S. patents in one year
Despite a shortened trading week, we made a series of moves, including initiating a position in GSV Capital.
First efficacy trial to evaluate Inovio's cancer immunotherapy targeting HPV in combination with durvalumab
We'll sell some Inovio Pharma on recent strength and put 2 'pot names,' Kush Bottles and Corbus Pharmaceuticals, in the Bullpen.
During a quiet week for the market, we added to two positions and trimmed three others.
Inovio to receive $23 million in upfront payment; an additional $20 million in future regulatory milestone payments and double-digit tiered royalties on sales
We will buy more AcelRx Pharmaceuticals and sell shares of Inovio Pharmaceuticals as we close out 2017.
During another busy week, we rang the register and exited our position in Amplify, trimmed another name twice and scaled into a recent addition.
Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the August 2018 expiration.
Last week was a busy one for the portfolio, as we made a number of trades and saw outsized gains in several positions.
We're reducing our position in Inovio Pharmaceuticals and raising our rating on Hudson Technologies.
We bought into some tech names last week as a rotation occurred in the sector.
New strategic position will guide product discovery and scientific collaborations
Former Chief Marketing Officer at Merck Also Brings Women's Health Management Expertise
For the second week in a row, we initiated a new position, this time in a security tech name.
Inovio continues to investigate pre-treatment biomarkers which could identify patients most likely to respond to treatment with VGX-3100, increasing absolute efficacy of the product
We initiated a new position for the portfolio during the shortened holiday trading week.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.